| INTRODUC TI ON
Cytomegalovirus (CMV) is a globally ubiquitous double-stranded DNA virus of the Herpesviridae family, with seroprevalence rates ranging from 30% to 97%. [1] [2] [3] The virus establishes a persistent infection that is usually asymptomatic 4 ; however, it can cause substantial morbidity and mortality in immunocompromised transplant recipients, particularly those receiving a kidney transplant. 5 Furthermore, transplant recipients can develop CMV reinfection, defined as the detection of a CMV strain that is distinct from the strain that caused their initial CMV infection. 6 CMV reactivation has occurred if 2 strains are found to be indistinguishable either by sequencing specific regions of the viral genome or by using molecular techniques that examine genes known to be polymorphic. 6 Common complications associated with CMV disease in transplant recipients include CMV pneumonitis, increased risk of bacterial and fungal infections, and decreased overall survival. 1, 7 Furthermore, CMV-seronegative transplant recipients receiving an organ from a CMV-seropositive donor have the highest risk of developing CMV disease. 1 Currently, first-line treatment for prophylaxis of CMV disease in solid-organ transplant recipients is valganciclovir, an antiviral therapy (AVT). 8 In kidney transplant recipients, high-dose valaciclovir prophylaxis has been shown to be effective for the prevention of CMV disease and CMV viremia. 8 AVTs for the treatment of CMV disease in kidney transplantation include off-label leflunomide, 9 foscarnet for ganciclovir-resistant CMV disease, 8 and cidofovir for kidney transplant recipients with ganciclovir-and foscarnet-related mutations that do not confer cidofovir resistance. 8 In addition, a number of AVTs are currently in development, such as maribavir 10 and brincidofovir, 11 and letermovir is indicated for prophylaxis of CMV disease in hematopoietic cell transplant (HCT) recipients. 12 AVTs for prophylaxis of CMV is associated with the development of adverse events (AEs), particularly neutropenia. 13 Therefore, due to the safety concerns associated with AVTs, there is an unmet need for treatments with new mechanisms of action.
ASP0113 is a first-in-class, DNA-based vaccine designed for the prevention of CMV infection in at-risk transplant recipients.
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ASP0113 is a bivalent DNA vaccine containing the plasmids VCL-6365 and VCL-6368 (1:1 mass ratio) that encode glycoprotein B (gB) and phosphoprotein 65 (pp65), formulated with poloxamer CRL1005 and benzalkonium. 14 The safety and immunogenicity of ASP0113 has been demonstrated in healthy CMV-seronegative and CMV-seropositive adults in a phase 1 study, 15 and its efficacy and safety has been investigated in a randomized, double-blind, placebo-controlled, phase 2 study for the treatment of CMV in allogeneic HCT recipients. 2 In this aforementioned study, there were no statistically significant differences in the primary endpoint (rate of initiation of CMV-specific AVTs) between transplant recipients treated with 5 doses of ASP0113 (5 mg) and those receiving placebo.
However, ASP0113 significantly reduced the occurrence (P = .008) and recurrence (P = .017) of CMV viremia, and improved the time to event for viremia episodes compared with placebo (P = .003). is currently in phase 3 development for the reduction of overall mortality and the prevention of CMV end-organ disease in CMVseropositive, allogeneic HCT recipients (NCT01877655).
Here, we report the results of a double-blind, placebo-controlled phase 2 study to investigate the efficacy, safety, and immunogenicity of ASP0113 for the prevention of CMV viremia in CMV-seronegative transplant recipients receiving a kidney from a CMV-seropositive donor.
| MATERIAL S AND ME THODS

| Study design
This was a phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and immunogenicity of ASP0113 in CMV-seronegative transplant recipients who received a kidney transplant from a CMV-seropositive donor (NCT01974206).
The study was conducted at 52 sites in 6 countries (USA [32], Germany [5] , Canada [4] , France [4] , Spain [4] , and Australia [3] ).
An independent ethics committee (IEC) or institutional review board (IRB; protocol number 0113-CL-2001) reviewed the ethical, scientific, and medical appropriateness of the study before it was conducted. IEC/IRB approval of the protocol, informed consent, and transplant recipient information were obtained prior to the P = .307). There were similar numbers of transplant recipients with treatmentemergent adverse events between groups; however, more transplant recipients reported injection site pain in the ASP0113 group compared with placebo. ASP0113 did not demonstrate efficacy in the prevention of CMV viremia in this CMV-seronegative kidney transplant population, but demonstrated a safety profile similar to placebo.
ClinicalTrials.gov registration number: NCT01974206.
K E Y W O R D S
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Cytomegalovirus (CMV), kidney transplantation/nephrology authorization of vaccine shipment to a study site (see Supplementary Responders were defined as a change from a negative to a positive result (ex vivo and cultured ELISpot assays) or an increase in pp65-specific IFN-γ-secreting T-cell level of >2-fold, relative to baseline.
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The QuantiFERON ® -CMV T-cell assay measured the amount of IFN-γ produced by CMV peptide-stimulated T cells, classifying subjects as positive, negative, or indeterminate (as per QuantiFERON ® manufacturer guidelines, QIAGEN, Germantown, MD). 16 Responders were also defined as postvaccine increases in serum gB antibody levels ≥4-fold relative to baseline (measured by enzyme-linked immunosorbent assay 15 converted to a Meso Scale Discovery assay).
Adverse events were recorded from the day that recipients provided their informed consent, until 1 year after first study vaccine
injection. An independent data monitoring committee oversaw the safety of transplant recipients and conducted futility analyses, and
an adjudication committee judged all cases of CMV syndrome, CMV tissue-invasive disease (CMV end-organ disease), initiation of CMVspecific AVTs, and CMV-related deaths.
| Transplant recipients
Transplant recipients were eligible for the study if they were ≥18 years of age or the legal age of consent (whichever was greater), were CMV inclusion and exclusion criteria were pre-specified.
| Endpoints
The primary efficacy endpoint was the proportion of transplant recipients with CMV viremia (defined as a plasma viral load of ≥1000 IU/mL by central laboratory assay) from Day 100 through 1 year after first study vaccine injection.
Secondary endpoints (measured through 1 year after first study Immunogenicity endpoints (through 1 year after first study vaccine injection) were T-cell responses to pp65-and gB-specific antibody levels.
| Statistical analyses
Efficacy analyses were conducted using the full analysis set, which was a modified intention-to-treat analysis set that included all randomized transplant recipients who received at least one dose of randomized study vaccine, and who had at least one viral load assessment by the central laboratory within 1 year after first study vaccine injection. The primary endpoint was analyzed using the prespecified Cochran-Mantel-Haenszel test at the one-sided 5% level, stratified by the use of ATG, and by receipt of a kidney from a living or deceased donor.
Safety was summarized for all randomized transplant recipients who received at least one dose of study vaccine.
The sample size for this study was planned based on pooled results from 2 previous studies using weighted averages, 17, 18 which found that the placebo rate was 46% (70% weight on the study by Humar et al). Using a one-sided test with a type 1 error rate of 5%, a sample size of 64 transplant recipients (per arm) was predicted to allow for an 80% power to detect a reduction in CMV viremia to 25%
after
| RE SULTS
| Transplant recipient disposition and demographics
Overall, 184 transplant recipients were screened for inclusion, of whom 150 were randomized and 149 received at least one dose of study vaccine (75 in the ASP0113 group and 74 in the placebo group; Figure 1 ). Of these, 72 transplant recipients (96%) in the ASP0113 group and 69 transplant recipients (93%) in the placebo group completed treatment.
The majority of transplant recipients (N = 149) were white (79%) and male (73%), with a mean age of 49.3 years, and a mean body mass index of 27.8 kg/m 2 . Among the donors, the majority were white (65%) with a similar percentage of males (47%) and females (53%), and a mean age of 45.1 years. Overall, no differences between treatment groups or between recipient and donor demographic characteristics were observed (Table 1) .
| CMV viremia
There was no statistically significant difference in the primary endpoint of CMV viremia ≥1000 IU/mL between the ASP0113 and placebo groups (P = .307) ( Table 2 ).
There were minimal differences for the primary endpoint between the 2 groups when stratified by prior use of ATG and by receipt of a kidney from a living or deceased donor. However, the number of transplant recipients in each group after stratification was low.
There were no statistically significant differences between the ASP0113 and placebo groups for time to experiencing first CMV viremia ≥1000 IU/mL (Figure 2A ) or time to experiencing first adjudicated CMV-associated disease ( Figure 2B ). Furthermore, no statistically significant differences were seen between the ASP0113 and placebo groups for any of the secondary efficacy endpoints (Table 3 ).
There were no differences between the ASP0113 and placebo groups with regard to graft survival after 1 year (n = 71/71 No statistically significant differences between the ASP0113 and placebo groups were observed for any of the exploratory efficacy endpoints (Table 4 ).
| Immunogenicity
Mean T-cell response to pp65 and mean gB antibody level were similar between transplant recipients receiving ASP0113 versus placebo ( Figure 3 ). 
| Safety
Overall, treatment-emergent AEs (TEAEs) were experienced by a similar number of transplant recipients in the ASP0113 group (n = 75
[100%]) compared with the placebo group (n = 73 [99%]; Table 5 ). were not deemed to be drug related by the investigator.
No clinically meaningful differences between treatment groups were observed for changes in laboratory values, vital signs, or physical examinations. .545
TA B L E 4 Exploratory efficacy endpoints
BPAR, biopsy-proven acute rejection; CI, confidence interval; CMV, cytomegalovirus; eGFR, estimated glomerular filtration rate; NA, not applicable; NE, not estimable; OR, odds ratio; RR, relative risk; SD, standard deviation. 
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